-
Illumina Reports Financial Results for Third Quarter; EPS $.30
Tuesday, October 26, 2010 - 4:15pm | 145Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of 2010. Third quarter 2010 results: Revenue of $237.3 million, a 50% increase over the $158.4 million reported in the third quarter of 2009. GAAP net income for the quarter of $35.4 million, or $0.24...
-
Furiex
Tuesday, October 26, 2010 - 2:39pm | 804Furiex Pharmaceuticals (FURX) breaks down like this: 1) It is a spin-off from PPDI with ideal spin-off dynamics. That means that it appeared in the portfolio of many mid-to large cap mutual funds and due to its micro cap size it was indiscriminately sold. Boo-ya! We have selling pressure driven...
-
Rude Shock for Arena Pharma - Analyst Blog
Monday, October 25, 2010 - 2:33pm | 533The US Food and Drug Administration (FDA) dealt a major blow to Arena Pharmaceuticals (ARNA) by refusing to approve the company's obesity candidate lorcaserin citing tumor-related safety concerns. The US regulatory authority issued a complete response letter (CRL) stating that the efficacy of the...
-
Standpoint Initiates Buy Rating on ICON (ICLR)
Monday, October 25, 2010 - 12:04pm | 32Standpoint Research is initiating coverage on ICON plc (NASDAQ: ICLR) with a Buy recommendation and 2011-2012 price target of $28. ICON is currently trading at $19.98
-
Earnings Preview: Waters - Analyst Blog
Monday, October 25, 2010 - 11:33am | 886Waters Corp. (WAT) is slated to report its third quarter 2010 earnings on October 26, 2010 before the opening bell. The current Zacks Consensus Estimate for the third quarter is 97 cents per share, representing a year-over-year growth of 4.3%. Waters has surpassed earnings estimates consistently...
-
FDA Issues Complete Response For Arena's Lorcaserin
Monday, October 25, 2010 - 10:08am | 131On 10/23, Arena Pharmaceuticals (NASDAQ: ARNA) announced the FDA issued a complete response letter (CRL) for lorcaserin, citing several reasons for delaying the drug's approval. The CRL focused on lorcaserin's potential cancer risk and modest clinical efficacy, requesting additional preclinical...
-
Oppenheimer Expects Another Strong Quarter From Illumina
Monday, October 25, 2010 - 8:25am | 116This morning, Oppenheimer said that it is expecting another strong quarter from NGS market leader Illumina, Inc. (NASDAQ: ILMN). “We forecast sales of $224M ahead of the consensus estimate of $218M,” Oppenheimer writes. “Our EPS estimate of $0.24 is in line with the Street. We expect ILMN will once...
-
Benzinga's Top Downgrades (ETR, PRXL, BNCL, ATHN)
Monday, October 25, 2010 - 8:01am | 143Entergy Corporation (NYSE: ETR) was downgraded by UBS from "buy" to "neutral." ETR's shares closed at $ 74.59 on Friday. Entergy's 52-week trading range is $69.62-$82.53. Oppenheimer downgraded PAREXEL International Corporation (NASDAQ: PRXL) from “outperform" to "perform." PRXL's stock closed at...
-
Encorium Announces NASDAQ Panel Decision to Delist Common Stock
Friday, October 22, 2010 - 9:03am | 61Encorium Group, Inc. (Nasdaq: ENCO) today announced that, on October 20, 2010, it received notification that a NASDAQ Listing Qualifications Panel has determined to delist the Company's securities from The NASDAQ Stock Market, effective with the open of business on October 22, 2010, as a result of...
-
Benzinga's Volume Movers (ICLR, TZOO, ALXN, MAT)
Thursday, October 21, 2010 - 11:40am | 148ICON Plc (NASDAQ: ICLR) shares moved up 2.37% to $20.56 at 11:28 am. The volume of ICLR shares traded was 2323% higher than normal. ICLR reported 2% y/y rise in its Q3 net revenue. Travelzoo Inc (NASDAQ: TZOO) shares rose 13.11% to $30.29. The volume of TZOO shares traded was 1181% higher than...
-
Rude Shock for Amylin - Analyst Blog
Wednesday, October 20, 2010 - 7:09pm | 635Amylin Pharmaceuticals, Inc. (AMLN) suffered a huge setback recently when the US Food and Drug Administration (FDA) issued a second complete response letter (CRL) for Bydureon, Amylin's main pipeline candidate. Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), were...
-
Collins Stewart Lowers Amylin Price Target
Wednesday, October 20, 2010 - 11:13am | 171Collins Stewart reports that last night Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that the FDA issued a Complete Response Letter (CRL) for Bydureon, requesting a thorough QT (tQT) study (at supratherapeutic doses of Bydureon) and P3 DURATION-5 study data (Bydureon (commercial) vs....
-
Architecture Indexes Back to Pre-Recession Levels
Tuesday, October 19, 2010 - 10:52pm | 350Washington, D.C. – October 20, 2010 – "For the first time since January 2008, the Architecture Billings Index (ABI) indicated a growth in design activity in September, increasing for the fourth straight month. As a leading economic indicator of construction activity, the ABI reflects the...
-
WuXi Pharma Enters Oversold Territory - Tale of the Tape
Tuesday, October 19, 2010 - 2:39pm | 110WuXi PharmaTech (Cayman) Inc.'s (WX) share price has entered into oversold territory with a stochastic value of 13.33. The Zacks Consensus Estimate on the company's earnings for year ending 2010 increased by 4 cents over the past month to $1.01 per share. WuXi Pharma is a Zacks #2 Rank (“Buy”)...
-
Benzinga's Top Pre-Market NASDAQ Gainers (CSCX, ACLS, TSPT, QGEN)
Tuesday, October 19, 2010 - 8:24am | 165Cardiac Science Corporation (NASDAQ: CSCX) surged 9.05% to $2.29 in the pre-market session. Opto Circuits has agreed to purchase all the outstanding shares of CSCX for $2.30 per share, representing a 10% premium to the CSCX's closing price on October 18. Axcelis Technologies Inc (NASDAQ: ACLS)...